Parkinson’s disease as a result of aging

Manuel Rodriguez, †, 2 Clara Rodríguez-Sabate, † Ingrid Morales, †, 2 Alberto Sánchez † and Magdalena Sabate 3
1 Laboratory of Neurobiology and Experimental Neurology, Department of Physiology, Faculty of Medicine, University of La Laguna, La Laguna, Spain
2 Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNEC), La Laguna, Spain
3 Rehabilitation Service, Department of Pharmacology and Physical Medicine, Faculty of Medicine, University of La Laguna, La Laguna, Spain

Summary

Key words: aging; dopamine; nigrostriatal neurons; neurodegeneration; Parkinson’s disease.

Aging is characterized by a progressive decline of many physiological functions, an increased susceptibility to certain diseases, and an increase in the likelihood of death. It is a complex phenomenon that may be very diverse in the different animal species, in individuals of the same species, and in the different tissues of the same individual (Miller, 1999; Takubo et al., 2002; de Magalhaes & Costa, 2009). Although there are a number of different theories to explain the onset and progression of aging, it is generally accepted that aging is not the result of one single cause. The causal agents and the mechanisms that collaborate to produce aging can be divided into two groups: passive agents inducing tissue damage which are not properly repaired and which accumulate throughout life (damage-based theories), and genetic agents that actively alter the physiological behavior of cells (programmed theories).

Both theory types generally assume that aging is a multifactor phenomenon where the equilibrium between cell damage and cell repair is progressively lost throughout life (multifactor hypothesis). This imbalance is not evoked in the brain in the same way in the different cell types, with the glial and the neuronal subgroups comprising each center showing a different aging rate (Goings et al., 2002; Jayapanal & Sedivy, 2008). This study revises the information available about a subgroup of neurons [dopamine neuron (DAn)] of a mesencephalic center [substantia nigra (SN)] which is involved in a neurodegenerative illness (Parkinson’s disease (PD)). PD is generally considered as a single clinical entity with a specific etiopathogenesis. The possibility that PD could be the consequence of the degeneration of neurons which are particularly vulnerable to aging processes is discussed here.

PD and aging

PD is a slow-progression neurodegenerative disorder with a high incidence in aged people. Aging is the greatest risk factor for PD (Driver et al., 2009; Collier et al., 2011), and the incidence of the illness in people over the age of sixty increases in an exponential way (Driver et al., 2009). Tables of the trends in the health of the older population in the United States show that PD is present in 0.02% of people who died between 45 and 54 years of age and in 8.77% of people who died over 85 years of age. The prevalence of other diseases (e.g. heart disease or Alzheimer’s disease) also increases with aging, but none of them show the marked increase found in PD whose prevalence increases more than 400 times with aging. In addition, aging has been considered as the most important determinant of the clinical worsening of patients with PD, even when compared with variables such as disease duration (Levy, 2007; Collier et al., 2011). The response to treatments (e.g. levodopa) is also hampered by the advanced age (Levy, 2007). Thus, aging is a variable which is always present in PD.

The marked influence of aging on PD could explain the scarce information referring to the illness before the 19th century (there are a few documents from ancient India and Greece, and from the middle ages in Europe referring to parkinsonian signs with names such as kampavata, paradoxos, and shaking palsy). The initial mortality rate (mortality rate independent of aging) was high before the 19th century, and most people did not reach the age where the incidence of PD becomes relevant. Life expectancy increased in such a way during the 19th century as to attract the attention of James Parkinson (1817). This increase was spectacular during the 20th century, making PD a very important health problem which in the USA alone affects 59 000 new people every year (Hirtz et al., 2007; Driver et al., 2009; Wirdefeldt et al., 2011).

Degeneration of dopamine cells in PD and aging

Neurodegeneration in PD occurs in different brain centers that also degenerate with age (locus coeruleus, pedunculopontine nucleus, etc.; Lohr & Jeste, 1988; Ransmayr et al., 2000; Shibata et al., 2006). The mechanisms involved in the degeneration of these centers are not very well known, which limits the possibility of comparing the PD and aging neurodegeneration in these centers. This is not the case of SN cells.
Parkinson’s disease as a result of aging, M. Rodriguez et al.

whose degeneration is currently considered as the hallmark of PD and whose change with aging has been extensively documented. Thus, most comments in this review will be focused on the neuronal degeneration in the SN.

The initial studies showing neurodegeneration in the SN of patients with PD also reported a marked neuronal loss in the SN of the healthy subjects included in the control groups of these studies (Hirai, 1968; McGeer et al., 1977; Stark & Pakkenberg, 2004; Mortera & Herculano-Houzel, 2012). These studies were focused on the SN because this center loses its characteristic dark gray color in the PD brain, which is normally produced by the accumulation of the pigment neuromelanin in a subgroup of SN neurons. PD showed a decrease in nigral pigmented neurons (Hirsch et al., 1988, 1989; Fearnley & Lees, 1991), which suggested that the selective degeneration of these cells could be a feature of this illness and that neuromelanin may be involved in this degeneration (Hirsch et al., 1988). However, healthy aged subjects also showed a decrease in pigmented cells (7-10% decrease per decade) (McGeer et al., 1988; Ma et al., 1999; Cabello et al., 2002; Stark & Pakkenberg, 2004; Fedorow et al., 2005; Halliday et al., 2006; Double et al., 2008; Rudow et al., 2008), suggesting that if neuromelanin was involved in PD, it could also be involved in aging-related neurodegeneration.

The neuromelanin accumulation in the SN neuron (SNn) is the result of dopamine (DA) oxidation, which, together with the therapeutic effects of levodopa therapy in PD and the DA decrease found in the striatum of these patients (Hornykiewicz, 2008, 2010), suggested the DA turnover as the basis of PD. The neuromelanin+ neuron count is not the best way to estimate the number of DAn because the pigment slowly accumulates throughout life (which hampers the identification of DAn in young subjects) and because a portion of pigment slowly accumulates throughout life (which hampers the neuron count) (McGeer et al., 1988; Gonzalez-Hernandez et al., 2004; Kordover et al., 2013). Immunohistochemical markers to detect proteins involved in the synthesis (e.g. tyrosine hydroxylase and L-dopa decarboxylase), degradation (monoamine oxidase), and membrane transport (dopamine transporter (DAT)) of DA proved to be a better procedure to estimate the number of DA neurons. Different studies in patients with PD reported neurodegeneration of SN cells expressing DAT (McGeer et al., 1977; Kastner et al., 1993; Miller et al., 1999; Chu et al., 2006; Rudow et al., 2008; Kordover et al., 2013; Ishibashi et al., 2014) and the enzymatic machinery necessary for the degradation of DA (Lloyd & Hornykiewicz, 1970; Grote et al., 1974; Robinson et al., 1977; Saura et al., 1997). This cell loss is often considered as being selective for PD and is generally used as the keystone to diagnose the illness with positron emission tomography and other methods. However, most studies also found a DAn loss in the SN of healthy aged subjects, with the quantity of the cell loss being the main difference between PD and aging. The nigral distribution of the DAn degeneration has also been proposed as being selective for PD, with the ventral tier of the posterior and lateral regions of the SN compacta showing the highest degeneration rate (Fearnley & Lees, 1991; Damier et al., 1999; Rodriguez Diaz et al., 2001; Rodriguez et al., 2001). However, this DAn subgroup has also shown the highest rate of degeneration in aged monkeys (Kanaan et al., 2008; Collier et al., 2011) and healthy aged humans (Reeve et al., 2014), suggesting that the distribution of DAn degeneration is not selective for PD either.

On the other hand, the DAn degeneration during aging is a common phenomenon observed in animals and humans (Collier et al., 2011). A recent work on 750 aged brains of subjects which never showed a clinically defined PD reported a marked DAn loss in more than 30% of cases, which in addition showed other pathological characteristics of PD such as the Lewy bodies (Buchman et al., 2012). Most nigral DA neurons project to the striatum, forming the nigrostriatal DAn (snDAn) system. It has been found that the slow degeneration of these cells with aging may last for years without inducing clinical signs of PD, signs which cannot be found when the snDAn degeneration does not involve more than 50% of these cells or more than 70% of their synaptic terminals in the striatum. Thus, the difference between PD and aging brains could be a question of quantity (number of DAn lost) more than a question of quality (the type of cell which degenerates) (McGeer et al., 1988).

Physiological changes of DAn in PD and aging

DA neurons may experience physiological changes during aging that are similar to those observed in these cells before their degeneration in PD. The striatal decrease of DA observed in PD has also been found in the aged brain where the DA level decreases 10-13% per decade of life (Carlsson & Winblad, 1976; Riederer & Wuketich, 1976; Kish et al., 1992). The topographic distribution of the striatal DAergic denervation observed in PD (Kish et al., 1988; Hornykiewicz, 1989) has also been reported in the aged brain (Kish et al., 1992; Haycock et al., 2003). There are indications that an increase in DA turnover might be an early compensatory mechanism for DAn degeneration in PD (Barrio et al., 1990; Rodriguez & Castro, 1991; Sossi et al., 2002). A similar compensatory mechanism has been proposed for the age-related loss of DAn (Greenwood et al., 1991). There is evidence suggesting that msDAn surviving the SN degeneration may present a partial loss of their phenotypic characteristics in the PD (Kastner et al., 1993; Miller et al., 1999; Gonzalez-Hernandez et al., 2001, 2004; Chu et al., 2006), a fact that could explain why a portion of the melanin-positive SN neurons does not express TH or other dopaminergic markers in PD (Kordover et al., 2013). DAn degeneration probably begins in the distal axon and proceeds retrogradely (dying-back process) (Galvin et al., 1999; Cheng et al., 2010), inducing an early inhibition of the fast axonal transport (Coleman, 2005; Morfini et al., 2007; De Vos et al., 2008; Neukomm & Freeman, 2014) accompanied by a decreased expression of the dopaminergic phenotype (Bellinger et al., 2011; Cheng et al., 2011). A similar decrease in the dopaminergic phenotype has been found in the snDAn which survive to a partial degeneration of the nigrostriatal system (which may change its DAergic phenotype by a GABAergic phenotype) (Rodriguez & Gonzalez-Hernandez, 1999; Gonzalez-Hernandez et al., 2001), and in nigrostriatal cells of animals with a degeneration of the contralateral snDAn (Gonzalez-Hernandez et al., 2004). The phenotype of neurons may be also modified by aging (Tedroff et al., 1988; Volkow et al., 1996; Emborg et al., 1998; Mozley et al., 1999; Pirker et al., 2000; Gerhardt et al., 2002; Kanaan et al., 2007), a fact observed in SN neurons which gradually loss their DAergic phenotype with aging whereas preserve the cytoplasmic neuromelanin (McCormack et al., 2004). D1 and D2 dopamine receptors present a compensatory increase in the brain of untreated PD (Lee et al., 1978; Centonze et al., 2003), an event also found in the aged brain (Grote et al., 1974; Morgan et al., 1987; Suhara et al., 1991; Wang et al., 1998b) (although some inconsistent data have also been reported) (Hess et al., 1987; Suhara et al., 1991; Wang et al., 1998b). Thus, functional changes observed in the msDAn surviving the PD neurodegeneration have also been found during healthy aging. Most of these changes are probably an attempt by the surviving neurons to compensate for the partial degeneration of the other DA neurons (increase of DA turnover and DA receptors) or to prevent their own degeneration (loss of phenotypic characteristics),
Degeneration of nondopamine neurons in PD and aging

As mentioned above, the snDAn is not the only neuron which degenerates in PD. DA neurons of the ventral tegmental area and retrorubral field (…), and other neurons interconnected with these cells such as the noradrenergic neurons of the locus coeruleus (…), cholinergic neurons of the pedunculopontine nucleus (…), and glutamatergic neurons of the intralaminar thalamic nucleus (…), also degenerate in PD. In addition, PD neurodegeneration has been found in neurons not directly interacting with the snDAn, such as those of the myenteric plexus or the olfactory bulb. The mechanisms involved in the loss of non-DA neurons have been little studied, and there is evidence supporting the idea that PD degeneration begins in non-DA neurons and then progresses to DA neurons (Braak et al., 2003; Ferrer et al., 2011), but also supporting the possibility that the degeneration of non-DA neurons could be induced by the previous degeneration of DA neurons (Morales et al., 2013a,b). In any case, the parkinsonian degeneration observed in most non-DA neurons has also been found in the healthy aged brain (Iversen et al., 1983; Baker et al., 1989; Manaye et al., 1995; Arango et al., 1996; Ransmayr et al., 2000), which also presents the cytosolic aggregates reported in the PD brain (e.g. Lewy bodies) (Mann, 1983; Halliday, 2009). The systematic study of cases with protein aggregate pathology has prompted a staging classification of PD based on the putative progression of Lewy body pathology from the medulla oblongata and olfactory bulb to the midbrain, diencephalon, and neocortex (Braak et al., 2002, 2003; Muller et al., 2005; Braak et al., 2006). In the aforementioned proposals, the DAn degeneration is not substantial (<60% of cell loss) before stage 3 is reached, with stages 1 and 2 being characterized by the presence of aggregates outside the SN (e.g. myenteric plexus, dorsal IX/X motor nuclei, intermediate reticular zone, caudal raphe nuclei, locus coeruleus, and olfactory bulb) and by the existence of nonmotor clinical disturbances (Jellinger, 2002; Ferrer et al., 2011). Much research is being carried out to identify early nonmotor signs which can be used to diagnose PD during its premotor stages. This trial is hampered by the fact that different mechanisms, including the α-synuclein that has escaped from axon terminals (which prevents its aggregation in DAn) (Braak et al., 2007; Song et al., 2009; Lee et al., 2010) and glutamate released from glutamatergic neurons (which prevents its excitotoxic action) (Rodriguez et al., 2012, Morales et al., 2013a,b). These protective activities decrease during aging. Astrocytes cultured from the brain of aging rats show morphologic and staining (e.g. beta-galactosidase.) patterns which are characteristic of senescence, reducing their ability to protect neurons (Mansour et al., 2008, Chinta et al., 2013). These senescent astrocytes are involved in the neuronal loss in the aged brain (Pertusa et al., 2007). Similarly, the neuroprotective actions of astrocytes decrease in PD (Mirza et al., 2000; Song et al., 2009), which shows a low level of glutathione in the SN (≈40%) (Sian et al., 1994) and an increased vulnerability of DAn to free radicals (Pearce et al., 1997). These facts are probably important for the onset and progression of PD (Halliday & Stevens, 2011).

On the other hand, astrocytes can actively induce neurodegeneration by different mechanisms, including the release of cytokines/TNFs (Lee et al., 2010) (e.g. in response to an excessive accumulation of α-synuclein) (Wakabayashi et al., 2000; Lee et al., 2010) and the release of glutamate (Mansour & Rodriguez, 2012; Morales et al., 2013a,b). The astrocytic release of toxic agents can be facilitated by reactive astrogliosis, a global reaction of astrocytes to brain damage (Sofroniew & Vinters, 2010). Reactive gliosis has also been implicated in the deterioration of both the aging (Goss et al., 1991; Kohama et al., 1995; Hayakawa et al., 2007; Lynch et al., 2010) and the PD brain (Rogers et al., 2007; Werner et al., 2008). Thus, it is possible that an imbalance between the protecting vs. damaging actions of astrocytes on neurons during aging could also explain the marked action of aging on PD (Damier et al., 1993; Lin et al., 1993; Venkateshappaa et al., 2012). The astrocyte population is normally replenished by new astrocytes derived from stem cells of the subventricular zone (Gonzalez-Perez & Quinones-Hinojosa, 2012; Mack & Woolburg, 2013). The reduction in gliogenesis induced by the senescence of the subventricular zone during the last third of life (Hoglinger et al., 2004; Galvan & Jin, 2007, Conover & Shook, 2011; Shook et al., 2012) is another circumstance to explain the aging of astrocytes and, consequently, the aging and death of DA neurons.

Microglia is normally found in a quiescent resting state with a small soma and highly ramified processes that contact neuronal synapses (Davalos et al., 2005; Nimmerjahn et al., 2005; Wake et al., 2009). In response to brain injury, the microglial cell shortens its branches, thereby suggesting that the physiological response to the partial loss of the nsDAn system could be similar in the PD and aged brain.

The involvement of non-neuronal cells in PD and aging

The anomalous activity of glial cells has been involved in the progression of PD. Although the glial dysfunctions of PD are frequently considered as being specific to the illness, most of them have also been observed in the aged brain. Both aged and PD brains present a low-level chronic inflammation (‘neuro-inflammaging’) with complex changes in the activity of astrocytes and microglia (Franceschi et al., 2007; Chung et al., 2009). Both cells may produce detrimental effects on neighboring neurons due to chronic production of pro-inflammatory agents (ROS, leukocyte-attracting cytokines, etc.). However, both cells may also provide structural, metabolic, and trophic support to neurons (Allen & Barres, 2009; Chung et al., 2009; Nagelhus et al., 2013). This ambivalent activity is hampering the study of the role of the glial cells in PD.

Astrocytes are involved in a variety of physiological functions (Benaroch, 2009, Sofroniew & Vinters, 2010, Rodriguez et al., 2012) and whose deterioration has been linked to both PD and aging (Ravich et al., 1999; Sofroniev & Vinters, 2010; Belanger et al., 2011; Rodriguez et al., 2012, Morales et al., 2013a). These cells may behave in an opposing manner, promoting damage or providing protection to neurons. Astrocytes synthesize glutathione (Rice & Russo-Menna, 1998) whose release protects neighboring cells from oxidation (Hirrlinger et al., 2002), a protection which is lower in PD (Zeevahk et al., 2008). Astrocytes produce trophic factors (basic fibroblast growth factors, mesencephalic astrocyte-derived neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF), etc.) that protect the DAn from damage (Lin et al., 1993; Saavedra et al., 2006; Deierborg et al., 2008). In addition, astrocytes remove toxic molecules from the extracellular medium, including the α-synuclein that has escaped from axon terminals (which prevents its aggregation in DAn) (Braak et al., 2007; Song et al., 2009; Lee et al., 2010) and glutamate released from glutamatergic neurons (which prevents its excitotoxic action) (Rodriguez et al., 2012, Morales et al., 2013a,b). These protective activities decrease during aging. Astrocytes cultured from the brain of aging rats show morphologic and staining (e.g. beta-galactosidase.) patterns which are characteristic of senescence, reducing their ability to protect neurons (Mansour et al., 2008, Chinta et al., 2013). These senescent astrocytes are involved in the neuronal loss in the aged brain (Pertusa et al., 2007). Similarly, the neuroprotective actions of astrocytes decrease in PD (Mirza et al., 2000; Song et al., 2009), which shows a low level of glutathione in the SN (≈40%) (Sian et al., 1994) and an increased vulnerability of DAn to free radicals (Pearce et al., 1997). These facts are probably important for the onset and progression of PD (Halliday & Stevens, 2011).

© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
enlarges its somata, and expresses macrophage markers (Streit et al., 1989; Ito et al., 1998), thereby promoting the release of cytokines, chemokines, and ROS (Kreutzberg, 1996), and activating its migration (Kreutzberg, 1996) and phagocytic action (Streit, 2002; Doorn et al., 2012). This microglial reaction has been observed in PD (Hunot et al., 1996; Knott et al., 2000; Croisier et al., 2005; Orr et al., 2005), where it can be activated in response to aggregated (Zhang et al., 2005) and nitrated (Mor et al., 2003) forms of α-synuclein, thereby promoting the internalization and degradation of this protein (Zhang et al., 2005). Although the microglial reaction could be initially useful (e.g. preventing the accumulation of the α-synuclein in the Lewy bodies of DAn), its chronic action can promote the DAn degeneration in PD (Halliday & Stevens, 2011). Similar chronic activation of microglia has been observed in the aging brain (Godbout & Johnson, 2004; Flanary, 2005; Gelinas & Stevens, 2011). Similar chronic activation of microglia has been observed in the aging brain (Godbout & Johnson, 2004; Flanary, 2005; Gelinas & Stevens, 2011). Thus, the behavior of microglia also seems to be similar in the PD and aged brain.

Therefore, the action of aging on astrocytes and microglia seems to be important for the DAn degeneration observed in aging and PD. A similar conclusion is suggested by studies with pluripotent stem cells (Takahashi & Yamanaka, 2006) which in vitro differentiated to DAn. These neurons only present the typical characteristics of the degenerating parkinsonian DAn (reduced numbers of neurites, accumulation of α-synuclein, etc.) when they are aged in vitro (Sanchez-Danes et al., 2012; Isobe et al., 2014).

The cause of PD and aging: the multifactor hypothesis

Although definitive conclusions about the etiology of PD have not been reached, it is generally considered that this illness is the consequence of the simultaneous action of a number of toxic and genetic agents able to degenerate the DAn in animals and humans (multifactor hypothesis of PD) (Olanow & Tatton, 1999; Bossy-Wetzel et al., 2004; Litvan et al., 2007a,b; Obeso et al., 2010). The combination of these damaging agents might not be exactly the same in all patients, which may explain the high clinical diversity observed in PD. A similar multifactor etiopathogenic hypothesis has been proposed for the brain aging of healthy subjects (Olson, 1987; Peto & Doll, 1997). As will be shown, most (if not all) agents included in the multifactor hypothesis of PD have also been included in the multifactor hypothesis of aging, thereby linking their etiopathologies (Table 1) (see at the end of the section “The cause of PD and aging: the multifactor hypothesis”.

Oxidative stress in PD and aging

The oxidative stress theory of aging proposed by Denham Harman in the 1950s states that the age-related loss of physiological functions is due to the progressive accumulation of oxidative damage (Harman, 1956). Nowadays, practically all theories implicate oxidative stress in cell aging (Gerschman et al., 1954; Brack et al., 2000; Toussaint et al., 2000; Jang & Van Remmen, 2009). The mitochondrial production of energy generates unpaired electrons (mainly in the complexes I and III) which facilitate the production of reactive oxygen (ROS) and nitrogen (RNS) species, damaging essential constituents of the cell (proteins, lipids, nucleic acids, etc.) (Sohal & Weindruch, 1996; Catatay et al., 2003; Kayali et al., 2009; Murphy, 2009; Perez et al., 2009; Oliveira et al., 2010) and accelerating aging (Sohal & Brunk, 1992; Barja, 2002a). DAn could be particularly sensitive to oxidative stress and aging. The nsDAn has a very high number of synaptic terminals (up to 1 million per cell in humans) (Matsuda et al., 2009) and a thin unmyelinated axon (Orimo et al., 2011) which consume a high quantity of energy and which need local mitochondria to support their activity. If there were 10 mitochondria per synaptic terminals, then the total number of mitochondria in each DAn could be higher than 10 million, even when the axonal mitochondria are not included in the calculation. Bearing in mind that 0.2–2% of total oxygen consumption is converted into free radicals in the mitochondria (rather than into water) (Richter, 1992), the extremely high number of DAn mitochondria must generate a vast quantity of ROS whose toxic action during aging may be difficult to prevent. In addition, the DAn also produces ROS/RNS by other mechanisms, including DA metabolism by monoamine oxidase, DA autooxidation, and the Fenton reaction (these cells have a high concentration of iron) (Halliwell, 1992; Kidd, 2000; AhlSkog, 2005; Berg & Hochstrasser, 2006). Therefore, oxidative stress that promotes aging in all cells could be particularly dangerous in the DAn (Parker et al., 1989; Bender et al., 2006). The DAn is protected from free radicals by both nonselective mechanisms normally at work in all cells [superoxide dismutase (SOD) and glutathione peroxidase (GPX)] and selective mechanisms that are only operative in this cell. Examples of selective protecting mechanisms are the dopamine transporter (DAT) that moves DA from the extracellular to the intracellular medium, and the vesicular monoamine transporter 2 (VMAT2) that moves DA from the intracellular medium to synaptic vesicles. These agents protect DAn from the self-oxidation of DA, keeping the neurotransmitter away from the cell regions more vulnerable to oxidative stress and in an environment where the low pH decreases the oxidation rate.

Oxidative stress has been included in most models to explain the DAn degeneration in PD (Olanow & Tatton, 1999; Dawson & Dawson, 2003; Moore et al., 2005; Hwang, 2013). There is evidence showing a disruption of the mitochondrial electron transport chain (particularly of the complex I) which increases ROS generation in the PD brain (Parker et al., 1989; Shapiro et al., 2002; Bender et al., 2006). This deficiency was also observed in platelets (Parker et al., 1989) and other tissues (Orth & Schapira, 2002) of patients with PD and was confirmed with cybrid models made with platelets of patients with PD (Swedlow et al., 1996; Gu et al., 1998). The toxic effect of oxidative stress in the DAn has been tested in animals by administering drugs which, after blocking the mitochondrial complex I, induce a parkinsonian syndrome. These drugs include MPTP (Burns et al., 1983; Langston & Ballard, 1984; Ballard et al., 1985), rotenone (Ramsay et al., 1991; Betarbet et al., 2000), paraquat (Miller et al., 1978; Manning-Bog et al., 2002), and 6-hydroxydopamine (Ungerstedt, 1971; Rodriguez et al., 2001), which are drugs whose toxic action on the DAn have been contrasted in humans who received them unintentionally and who developed PD (Tanner, 1989; Semchuk et al., 1992, Gorell et al., 1998; Di Monte et al., 2002; Weisskopf et al., 2010). In addition, the mechanisms for nonselective (SOD and GPX; Riederer et al., 1989; Liu et al., 1994; Asanuma et al., 1998; Gonzalez-Zulueta et al., 1998) and selective (DAT and VMAT2) (Cruz-Muros et al., 2007a,b) DAn protection are downregulated in PD. The imbalance between the production of free radicals and the prevention of their toxic actions is probably at the basis of the high oxidative damage of lipids (Bosco et al., 2006), proteins, and DNA (Nakabeppu et al., 2007) found in the SN of the PD brain (Jenner, 2003, 2007). The same imbalance has been observed in the healthy aging brain.
Sohal & Brunk, 1992; Sohal & Weindruch, 1996; Barja, 2002b,a; Cakatay et al., 2003; Kayali et al., 2009; Perez et al., 2009; Oliveira et al., 2010). In keeping with this, procedures that retard aging in animals (particularly caloric restriction) normally increase resistance to oxidative stress (Sohal & Weindruch, 1996; Yu, 1996; Yu & Yang, 1996; Barja, 2002b,a; Bokov et al., 2004). Thus, available evidence suggests a direct link between the age-related oxidative stress and the DAn degeneration in PD. Although oxidative stress is normally included in the etiopathology of PD (Subramaniam & Chesselet, 2013), there is no agreement about its origin. Oxidative stress could be induced by the action of other cells on the DAn (e.g. by excitotoxicity) (Nguyen et al., 2011) or may simply be the consequence of aging.

Mitochondrial damage in PD and aging

Shortly after the discovery of the mitochondrial genome (mtDNA) and after the incorporation the mitochondrial damage to the oxidative stress hypothesis (Harman, 1972), the stress-related accumulation of mtDNA damage began to be considered as a major cause of aging (Miquel et al., 1980). Complex I is in close proximity to the mtDNA, and the inverse relationship between lifespan and ROS production (at complex I (Barja & Herrero, 2000; Lambert et al., 2007) has also been observed between lifespan and the number of mtDNA mutations (Vermulst et al., 2007). Human mtDNA is highly vulnerable to postnatal mutations not only because of its proximity to the electron transport chain (the source of 90% of ROS), but also because of its lack of protecting histones, and its high replication rate. If ROS-induced mtDNA mutations are not repaired quickly, then they will be propagated and fixed with the mitochondrial replication cycle where the G is replaced by T and C by A (Wang et al., 1999a). Thus, the mitochondrial replication produces a clonal expansion and a propagation of the mtDNA errors, amplifying tissue-specific mutations and inducing somatic mosaicism which increase with age (genetic drift) (Muller-Hocker, 1989, 1990; Fayet et al., 2002). The accumulation of mutations during life is much higher in the mtDNA (Chinnery et al., 1999) than in the nuclear DNA (Cantuti-Castelvetri et al., 2005; Reddy & Beal, 2005). As suggested by the 2’deoxyguanosine data, the mutating action of free radicals on aging is mainly induced in the mitochondrial genome, with the accumulation rate of the nuclear DNA mutations not being correlated with the maximum lifespan (Barja & Herrero, 2000). Sporadic random mutations of the mtDNA may not be enough to induce functional disturbances in young people. However, their accumulation throughout life deteriorates the normal physiology of cells (Cantuti-Castelvetri et al., 2005; Smigrodzki & Khan, 2005; Maruszak et al., 2006) and promotes aging (Harman, 1972; Linnane et al., 1989). Brain tissue is particularly susceptible to mutations (Vermulst et al., 2007), mostly when compared with other tissues which, as occurs with the liver, do not accumulate mtDNA mutations during most of a person’s life (Ameur et al., 2011). The accumulation of the mtDNA deterioration with aging could be particularly high in the SNn (Reeve et al., 2013), which normally presents a high number of deletions (>40% in healthy sixty-year-old subjects) (Bender et al., 2006). The influence of mtDNA on aging could help to explain why ultra-centenarians have a high content of mtDNA (He et al., 2014) and why the mtDNA background of some ethnic groups affects their lifespan (Raule et al., 2013).

The decrease in energy production is one of the consequences of mitochondria damage. The preservation of mitochondrial activity needs a number of mechanisms that consume a portion of the energy produced by the organelle. These energy-demanding mechanisms include those involved in the movement of mitochondria to the cell locus with the highest energy requirement (axons and synapses), in the repair of damaged mitochondria (including mtDNA), in the destruction of badly damaged mitochondria, and in the synthesis of new mitochondria. The healthy mitochondria produce much more energy than that required to maintain normal activity, a fact that changes with aging. The decrease in the energy resources in the aged cells may prevent the repair of the mitochondrial damage, thus precipitating the organelle in a vicious cycle (→ energy production ↔ mitochondrial repair) where the mitochondria behaves as both cause and consequence of aging (Lauri et al., 2014a). Mitochondrial damage similar to that found in the aging brain has been found in the PD brain where the accumulation of mtDNA mutations is usually higher in patients over 65 years of age (Krafft et al., 2006). mtDNA deletions in PD are a little higher than those observed in healthy aged subjects (52% vs. 44%) (Bender et al., 2006), data that also suggest that the difference between aging and PD is a matter of quantity more than a matter of quality.

Most data supporting the free radical theory of aging are correlative and do not directly prove this theory. On the other hand, there are data suggesting that the effect of oxidative stress on aging could be less relevant than frequently assumed. One way to directly test the free radical theory of aging is to manipulate the oxidative damage of mitochondria by modifying the expression of antioxidant proteins (Jang & Van Remmen, 2009). Studies with MnSOD, catalase, and thioredoxin knockout mice have provided inconclusive data to support the oxidative stress theory of aging ( Muller et al., 2007; Jang & Van Remmen, 2009; Sohal & Orr, 2012). However, these knockout mice models of aging and other aging models such as the SAMP8 (Takeda, 2009; Shimada & Hasegawa-Ishii, 2011) or the mtDNA mutator mouse (Edgar & Trifunovic, 2009; Lauri et al., 2014b) could be particularly useful to study the influence of aging on the DAn degeneration in PD (Liu et al., 2008; Dai et al., 2013). In addition, different approaches have reported non-oxidative mitochondrial dysfunctions. A number of age-associated structural changes (e.g. enlargement of mitochondria, alterations of the cristae structure, matrix vacuolization/densification) have been reported (Wilson & Franks, 1975; Herbener, 1976; Tate & Herbener, 1976). Dysfunctional mitochondria may be repaired by a fission/fusion process. However, the mitochondria must be eliminated by mitophagy when the damage is important, a selective type of autophagy that maintains a suitable number of functional mitochondria and prevents the accumulation of those that are nonfunctional. Excessive mitochondrial stress (Ethell & Fei, 2009) or modifications of proteins involved in the mitophagy modulation (e.g. parkin and PINK1) (Narendra et al., 2010; Van Humbeeck et al., 2011; Palikaras & Tavernarakis, 2012) disturb mitophagy and promote PD. The low clearance of dysfunctional mitochondria involved in the progression of PD has also been linked to aging (Palikaras & Tavernarakis, 2012), which presents low autophagic activity (Cuervo et al., 2004; Hubbard et al., 2012) whose recovery (e.g. using caloric restriction) promotes longevity (Yen & Klionsky, 2008). Other autophagic processes whose modification have been linked to aging are probably also involved in PD (Cuervo et al., 2004; Martinez-Vicente et al., 2008; Wong & Cuervo, 2010; Hubbard et al., 2012). The cytosolic components of the mammalian cell may be degraded by three complementary processes: macroautophagy, microautophagy, and chaperone-mediated autophagy. These processes sequester proteins and organelles from the cytoplasm and deliver them into the lysosomal compartment where they are degraded and eliminated (Mizushima et al., 2008; He & Klionsky, 2009). The downregulation of these autophagic mechanisms has been involved in age-related neurodegeneration (Shibata et al., 2006; Palikaras & Tavernarakis, 2012). There is also increasing evidence showing insufficient autophagy in neurodegenerative
disorders where this could explain the accumulation of proteins in cytosolic aggregates (e.g. of α-synuclein in Lewy bodies of PD) (Stefanis et al., 2001; Webb et al., 2003; Cuervo et al., 2004; Martinez-Vicente et al., 2008; Wong & Cuervo, 2010; Friedman et al., 2012). The identification of the autophagic disturbances in PD could provide new evidence to understand the age influence on PD, and perhaps for controlling both processes (Table 1).

An efficient mitochondrial quality control needs mechanisms to move this organelle between different cell regions. The axon of the snDan accounts for a high percentage of the cell volume (>95%) (Devor, 1999; De Vos et al., 2008) and uses a significant portion of its energy (Brookes et al., 2004). Thus, it contains a high number of mitochondria, a portion of which could be generated (Amiri & Hollenbeck, 2008) and restored (fusion/fission) (Court & Coleman, 2012) locally. However, only 13 of ≈1000 mitochondrial proteins are encoded by the mtDNA (Boore, 1999), which means that most synaptic and axonal mitochondria are probably synthesized in the neuronal somata and moved along the axon (>30% of axonal mitochondria are normally in motion) until reaching these distal structures (anterograde motion). In addition, axonal transport also moves dysfunctional mitochondria from synaptic bottoms and axons to the cell soma (retrograde motion) where they can be destroyed by mitophagy, lysosomes, and the ubiquitin-proteasome system (Cheng et al., 2010). Thus, the snDan survival needs efficient axonal transportation (Sasaki et al., 2005; De Vos et al., 2008; Florenzano, 2012) which may be hampered by the small diameter (<1 μm) and the intensive branching (hundred thousands of bifurcations) of this cell axon (Matsuda et al., 2009). This transportation is probably damaged in PD. There is evidence suggesting that PD starts with axonal damage and progresses by a ‘dying back’ process to the DAn somata (Cheng et al., 2010). Proteins that collaborate with the kinesins/dyneins system to transport mitochondria across axons (e.g. α-synuclein, parkin and PINK1-Miro-Milton complex) have also been implicated in PD (Bueler, 2009; Weihofen et al., 2009; Yang et al., 2010). Axonal disruptions have also been observed in aged neurons (Fjell & Walhovd, 2010), which show a deterioration of axonal transport (Gilley et al., 2012) and of the quality control (Sterky et al., 2011) of the mitochondria. Thus, PD and aging also present similar anomalies in the axonal transport and quality control of mitochondria.

Other biochemical pathways that could be useful to compare the mitochondrial deterioration in aging and PD are beginning to be studied. Pathways involved in the modulation of microRNAs (miRNAs) are an example of these new possibilities. miRNAs are small noncoding RNA species that play crucial regulatory roles in many biological processes including those involved in the mitochondrial-mediated aging (Lauri et al., 2014a). miRNAs can control senescence at multiple levels including the modulation of mitochondrial respiration, the modulation of genes involved in ATP and ROS production, and the regulation of autophagy (Zhao et al., 2010; Bai et al., 2011; Bandiera et al., 2011; Faraonio et al., 2012; Olivieri et al., 2012; Magenta et al., 2013). The modulating action of aging on miRNAs is probably different in each organ (e.g. in the liver and the brain), which could be helped to explain the different aging rate of tissues (Li et al., 2011). miRNAs are probably

| Table 1 Cell characteristics and mechanisms that are common to aging and Parkinson’s disease (PD) |
|------------------------------------------|----------|
| **Cellular changes** | **Etiology** |
| **SNn loss** | **Pathogenicity** |
| Melanin+ cells | ↓ ↓ |
| TH+ cells | ↓ ↓ |
| DD+ cells | ↓ ↓ |
| DAT+ cells | ↓ ↓ |
| Lat/Postdistribution | YES | YES |
| nsDan adaptation | YES | YES |
| DA turnover | ↑ ↑ |
| DA receptors | ↑ ↑ |
| DAT activity | ↓ ↓ |
| DAN differentiation | ↓ ↓ |
| PPN | Ach cells | ↓ ↓ |
| Locus coeruleus | NA cells | ↓ ↓ |
| Thalamus | GLU cells | ↓ ↓ |
| Astrocytes | Astroglia | YES | ? |
| Glutamatergic release | ↓ | ? |
| Trophic factor release | ↓ | ? |
| Cytokines, TNFα release | ↑ | ↑ |
| GLU release | ↑ | ? |
| Giogiosis | ↓ ↓ |
| Microglia | μ-gliosis | YES | YES |
| IL-1β/IL-6 release | ↑ | ↑ |
| Stem cells | SVZ proliferation | ↓ | ↓ |

**SNn**, substantia nigra neurons; nsDan, nigrostriatal dopamine neurons; TH+, cells with tyrosine hydroxylase immunoreactivity; DD+, cells with l-dopa decarboxylase immunoreactivity; DAT+, cells with immunoreactivity for the dopamine transporter; DA, dopamine; Ach, acetylcholine; NA, norepinephrine; GLU, glutamate; SVZ, subventricular zone; ETC, electron transport chain; ROS, reactive oxygen species; RNS, reactive nitrogen species; SOD, superoxide dismutase; GPX, glutathione peroxidase; mtDNA, mitochondrial DNA.

Not all data summarized here have the same experimental or clinical confidence level. The question mark is included when available data are scarce, incomplete, or contradictory.
important not only for the ontogenic differentiation of the DAn (Junn & Mouradian, 2007, but also for its deterioration with aging and PD (Kim et al., 2007; Harraz et al., 2011; Mouradian, 2012). Perhaps after certain methodological improvements (e.g. after preventing the low stability of miRNAs in the brain samples), the comparison of the aging and PD miRNA could be particularly useful to identify similarities and differences between the DAn in both conditions (Sethi & Lukiw, 2009).

In summary, mitochondrial damage is a central fact in the aged and PD brain. Both aging and PD present a slow-progression mitochondrial disturbance linked to a slow-course neurodegeneration lasting for many years. The mitochondrial deterioration rate is not the same in all tissues (which could explain the different aging rates observed in the different organs of the body), with the DAn being particularly vulnerable to the aged mitochondria (Conley et al., 2007; Lauri et al., 2014a). It is possible that some mitochondrial damages can be transmitted to the offspring, which could explain why the risk of developing PD may be greater in persons whose mother was affected by the disease than in those with affected fathers (Beal, 1998; Bonilla et al., 1999; Chinnery et al., 1999).

Genetic control of PD and aging

There are data suggesting that aging is genetically programmed in animals and humans (Austad, 2004; Longo et al., 2005; Przinger, 2005). Humans present a significant degree of heritability of longevity, and a mortality rate doubling time (time to double the probability of dying) which is constant among human populations (=8 years), even under different environmental conditions (Hjelmborg et al., 2006). However, the high number of genes involved (see GenAge database) and the partial relevance of most of them mean that genetic information cannot be used at present to predict the aging rate of individuals. This circumstance is also true for PD, where the polygenic low-penetration and the gene–environment interaction has led to much debate about the actual significance of genetic factors on sporadic PD (Sellbach et al., 2006; Wirdefeldt et al., 2011). The offspring of long-lived parents seem to be protected against age-related diseases (Atzmon et al., 2004), which suggests that the genetic control of aging is involved in neurodegenerative illnesses. At present, there is not enough information to compare the polygenic control of aging and PD, but there is clear evidence showing that genes that modulate the DAn vulnerability (whose mutation induces familiar parkinsonisms) are linked to normal aging. Some of these genes will be briefly referred to below.

In general, genes that modulate the oxidative stress (Muftuoglu et al., 2004; Palacino et al., 2004; Devi et al., 2008; Irrcher et al., 2010) and the quality control of mitochondria (Bueler, 2009; Weihofen et al., 2009; Yang et al., 2010; Narendra et al., 2010; Van Humbeek et al., 2011; Palikaras & Tavernarakis, 2012) have proved to be relevant for both PD and aging. α-synuclein (a protein involved in the recycling vesicles in DAergic synapses) (Abeliovich et al., 2000) may present anomalous conformations that facilitate the production of oligomeric species and amyloidogenic filaments whose aggregation and precipitation form the Lewy bodies found in nDAn of the PD brain (Lansbury & Brice, 2002). There are data showing that oxidative stress can promote the aggregation of α-synuclein in PD and other synucleinopathies (Gliason et al., 2000). α-synuclein presents a similar behavior in aging, promoting the accumulation of pathogenic proteins, the impairment of the ubiquitin-proteasome system, and the loss of DAn (Li et al., 2004; Moore et al., 2005). In the PD brain, the anomalous activity of parkin (a protein involved in the ubiquitination of proteins and in mitophagy) produces an improper targeting of substrates for proteosomal degradation and in a fragmentation of the mitochondrial network (Lucking et al., 1998, 2000; Moore et al., 2005; Reeve et al., 2014). Similar facts have been reported for parkin during aging (Rodriguez-Navarro et al., 2007; Vincow et al., 2013). Changes in the UCH-L1 (a protein that recycles free ubiquitin) activity may result in an impairment of the efficiency of the ubiquitin-proteasome system (Osaka et al., 2003; Li et al., 2004) which is involved in PD (Leroy et al., 1998). This protein has been proposed as an intracellular stress marker in cell aging (Marzbân et al., 2002). PINK1 phosphorylates mitochondrial proteins in response to cellular stress, thereby preventing mitochondrial dysfunctions and promoting (in cooperation with parkin) the degradation of damaged mitochondria by lysosomes and proteasomes (Valente et al., 2004a; Liu, 2014). The PINK1 activity is also involved in both PD (Valente et al., 2004b; Albanese et al., 2005; Gelmetti et al., 2008) and aging (Wood-Kaczmar et al., 2008; Vincow et al., 2013). DJ-1 is a ubiquitous protein located in neurons and glia, where it provides protection against oxidative stressors. The insoluble forms of DJ-1 are notably greater in the brains of patients with PD (Moore et al., 2005), and its mutation causes a familiar early onset of parkinsonism (Bonifati et al., 2003a, b; Ibanez et al., 2003). This protein has also been linked to aging (Marzbân et al., 2002; Meulener et al., 2006).

Although the influence of the above-mentioned genes in different familiar parkinsonisms is clear, its actual relevance in sporadic PD is less evident. In addition to the above-mentioned genes, many other genes can influence lifespan. The possible influence of a gene on lifespan can be found in GenAge, a database with information on over 700 genes (Tacutu et al., 2012; Budovsky et al., 2013). The possible relevance of most of these age-related genes on PD cannot be directly checked because there is not a gene bank for PD similar to GenAge (Wirdefeldt et al., 2011). Thus, it is not possible to compare the configuration of genes involved in PD and aging at present. Another limiting fact to consider is the complex genome–environment interaction that modulates the aging process and that probably influences the risk of PD. The regulation of single genes can extend the lifespan of some primitive organisms more than 10-fold (Ayyadevara et al., 2008). Although the genetic modulation of lifespan is more complex and less efficient in mammals, the advance in knowledge about the interaction of the age-related genes and the environment is starting to be used to extend the lifespan of these animals (de Magalhaes et al., 2012). Thus, the aging of certain mammals may be modulated by manipulating external (e.g. temperature, diet) and internal (e.g. by targeting the insulin-like group factor receptors, growth hormone receptors, sirtuins) variables (de Magalhaes et al., 2012; de Cabo et al., 2014). If, as the present review suggests, the age-related mechanisms are directly involved in PD, then the control of some of the environmental variables that have proved useful to modulate aging in animals (e.g. caloric restriction, hormesis, spermidine) could also be useful to control the onset and progression of PD. Some of these variables have already proved their efficacy in animal models of PD. This is the case of the caloric restriction whose utility to control aging has been proved in practically all animal species studied and which may decrease the vulnerability of the DAn to toxic agents (Duan & Mattson, 1999). There is some epidemiological (de Lau et al., 2005) and clinical (Vanitallie et al., 2005; Nunomura et al., 2007) studies suggesting that the caloric restriction and the control of diets (antiglycating agents...) could decrease the clinical expression and the evolution of PD (Wirdefeldt et al., 2011; Hipkiss, 2014). Sirtuin 1, a protein that mediates longevity under calorie restriction (Jadiya et al., 2011; Zhang et al., 2011), decreases in DAn which received dopaminergic neurotoxins such as rotenone, 6-hydroxydopamine, or MPTP (Alvira et al., 2007; Pallas et al., 2008; Albani et al., 2009; Jadiya et al., 2011; Srivastava &
Aging, silent toxics, and PD

The incidence of PD increases sharply toward the end of the fifth decade of life just as the effect of aging all over the body appears. The DAn degeneration considered as the hallmark of PD has also been observed in the aged brain where it is induced by most (if not all) agents involved in PD. The main difference between DAn degeneration in PD and aging seems to be a question of quantity (degree of cell loss) more than a question of quality (presence/absence of cell loss; McGeer et al., 1977; Kordower et al., 2013). Senescence is a wider phenomenon affecting practically all cells in the body, whereas PD has been restricted to some brain centers and cell populations. The present review suggests that PD may be the local expression of aging in some cell populations whose characteristics (high number of synaptic terminals and mitochondria, unmethylated axon) make them highly vulnerable to aging. If PD is the result of aging, a key question to consider is why only 4-5% of people develop the illness. In addition to the genetic characteristics of each individual, the environmental circumstances affecting each person throughout their life are different. Many circumstances capable of increasing DAn vulnerability present a toxic action which is not traumatic enough to induce clinical signs of PD in the short term (‘silent toxics’). Subjects who are highly exposed to silent toxics could present PD if their lifespan is long enough, whereas other people who are less exposed to silent toxics or with a short lifespan will never present PD. In these subjects, the compensatory mechanisms of the surviving DA neurons are sufficient to maintain the basal ganglia activity, and the age-related DAn loss induced by aging does not reach the threshold that triggers the motor disturbances. Thus, in these subjects (>94% of people under 70), the motor disturbances are not evident and the DAn degeneration goes unnoticed.

There are many silent toxic candidates. This is the case of pesticides and other chemical agents whose frequent presence in the environment may explain why farming, well water use, and rural living (normally accompanied by occupational exposure to herbicides, insecticides, and other chemicals) increase the risk of PD (Seidler et al., 1996; Gorenli et al., 1998; Di Monte et al., 2002; Coon et al., 2006; Hancock et al., 2008; Weiskopf et al., 2010). Other possible damaging agents could be the high consumption of dietary products or low physical activity (Wirdefeldt et al., 2002; Jeyapalan & Sedivy, 2008; de Cabo et al., 2014). This could explain why 50 years after first finding of DAn degeneration in sporadic PD, no specific causes for this illness have yet been found. In our opinion, more direct attention to the aging processes could accelerate the acquisition of new knowledge on the biological basis of PD, and actions aimed at delaying aging or promoting rejuvenation could also be useful to control the onset and progression of PD (Medvedev, 1981; Holliday, 1984). On the other hand, the considerable effort that is being made all over the world to understand the mechanisms involved in neurodegenerative illness should also contribute to clarifying the biological basis of aging.

Funding

No funding information provided.

Conflict of interest

None declared.

References

Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239–252.

Aihskog JE (2005) Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov. Disord. 20, 271–282.

Albanese A, Valente EM, Romito LM, Bellacchio E, Elia AE, Gallapiccola B (2005) The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64, 1958–1960.

Albani D, Polito L, Batei S, De Mauro S, Fraccaso C, Martelli G, Colombo L, Manzoni C, Saimona M, Caccia S, Negro A, Forlioni G (2009) The SIRT1 activator resveratrol protects SK-N-NE cells from oxidative stress and against toxicity.
Parkinson’s disease as a result of aging. M. Rodriguez et al.

Cakatay U, Telci A, Kayaill F, Tekeli F, Acavv T, Sivas A (2003) Relation of aging with oxidative protein damage parameters in the rat skeletal muscle. Clin. Biochem. 36, 51–55.

Campuzano O, Castillo-Ruiz MM, Aćvarin L, Castellano B, Gonzalez B (2009) Increased levels of proinflammatory cytokines in the aged rat brain attenuate injury-induced cytokine response after excitotoxic damage. J. Neurosci. Res. 87, 2484–2497.

Cantuti-Castelvetri I, Lin MT, Zheng K, Keller-McGandy C, Betensky RA, Johrs DR, Beal MF, Standaert DG, Simon DK (2005) Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiol. Aging 26, 1343–1355.

Carlsson A, Winblad B (1976) Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J. Neural. Transm. 38, 271–276.

Carvey PM, Chang Q, Lipton JW, Ling Z (2003) Prenatal exposure to the bacteriocin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson’s disease. Front. Biosci. 8, 826–837.

Centonze D, Grande C, Saull E, Martin AB, Gubellini P, Pavon N, Pisani A, Bernardi G, Moratalla R, Calabresi P (2003) Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J. Neurosci. 23, 8506–8512.

Cersosimo MG, Benarroch EE (2011) Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol. Dis. 45, 550–564.

Chao J, Yu MS, Ho YS, Wang M, Chang RC (2008) Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic. Biol. Med. 45, 1019–1026.

Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715–725.

Cheng HC, Kim SR, Oo TF, Kareva T, Yaginuma O, Rzhetskyaya M, Wang C, Dung M, Tallozy Z, Tanaka K, Konatsu M, Kobayashi K, Okano H, Khodolov N, Burke RE (2011) Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J. Neurosci. 31, 2125–2135.

Chinnery PF, Howell N, Andrews RM, Turnbull DM (1999) Mitochondrial DNA analysis: polymorphisms and pathogenicity. J. Med. Genet. 36, 505–510.

Chinta SJ, Lieu CA, Demaria M, Laberge RM, Campisi J, Andersen JK (2013) Environmental stress, ageing and glial cell senescence: a novel mechanistic link to Parkinson’s disease? J. Intern. Med. 273, 429–436.

Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH (2006) Nurr1 in vivo: the Yin-yang of sirtuins. Science 317, 461–462.

Doorn KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM (2012) Emerging roles of microglial activation and non-motor symptoms in Parkinson’s disease. Prog. Neurobiol. 98, 222–238.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Duan W, Mattson MP (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson’s disease. J. Neurosci. Res. 57, 195–206.

Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Cell. Mol. Life Sci. 60, 1546–1556.

Dillen A, Kelly JV (2007) Medicine: the Yin-yang of sirtuins. Science 317, 461–462.

Dong KJ, Lucassen PJ, Boddeke HW, Prins M, Berendse HW, Drukarch B, van Dam AM (2012) Emerging roles of microglial activation and non-motor symptoms in Parkinson’s disease. Prog. Neurobiol. 98, 222–238.

Duffy JL, Kley RL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog. Neurobiol. 92, 316–329.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.

Driver JA, Logrosino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72, 432–438.
Muller-Hocker J (1990) Cytochrome c oxidase deficient fibres in the limb muscle and diaphragm of man without muscular disease: an age-related alteration. J. Neurol. Sci. 100, 14–21.

Murphy MP (2009) How mitochondria produce reactive oxygen species. Biochem. J. 417, 1–13.

Nagelhus EA, Amyir-Moghadam M, Bergeners LH, Bjaalie JG, Eriksson J, Gundersen V, Leergaard TB, Morth JP, Storm-Mathisien J, Torp R, Walhovd KB, Tonjum T (2013) The glia doctrine: addressing the role of glial cells in healthy brain ageing. Mech. Ageing Dev. 134, 449–459.

Nakabesi Y, Tsuchimoto D, Yamaguchi H, Sakumi K (2007) Oxidative damage in nuclear acids and Parkinson's disease. J. Neurosci. Res. 85, 919–934.

Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, Youle RJ (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8, e1000298.

Neukomm LJ, Freeman MR (2014) Diverse cellular and molecular modes of axon degeneration. Trends Cell Biol. 24, 515–523.

Nguyen D, Alavi MV, Kim KY, Kang T, Scott RT, Noh YH, Lindsey JD, Wissing B, Ellisman MH, Weinreb RN, Perkins GA, Ju WK (2011) A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis. 2, e240.

Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. J. Neurosci. Res. 81, 101–113.

Nakao T, Kuzuhara S, Ito Y, Ikeda K, Kondo S, Hara Y, Shibayama A, Shimizu A, Tsuchida S, Ohata K, et al. (2003) Role of microglia in dopaminergic neuronal death in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. Res. 73, 590–600.

Nordberg A, Wisniewski T, Harrison M, Agid Y, Rapidé S, Jellinger K (1998) Mitochondrial dysfunction and oxidative damage in idiopathic Parkinson's disease. Ann. Neurol. 44, 615–623.

Nobile S, Bolognese F, Rugolo S, Piazzolla D, et al. (2012) Mitochondrial DNA mutations in patients with idiopathic Parkinson's disease. Neurobiol. Aging 33, 2610–2619.

Olanow CW, Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. Front. Genet. 3, 297.

Palacino JJ, Sakaguchi K, Vucic S, Rizzuto RG, Giunti P, Cuesta JC, Crespo-Biel N, Alvira D, Tajes M, Yeste-Velasco M, Folch J, Canudas AM, Sureda FX, Ferrer I, Camins A (2008) Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience 154, 1388–1397.

Paolini M, Sapone A, Gonzalez FI (2004) Parkinson's disease, pesticides and individual vulnerability. Trends Pharmacol. Sci. 25, 124–129.

Paik SW, Spillman PG, Babcock SD, Atwood CS, Poirier LA, Seidman MD (2009) Mitochondrial DNA point mutations are not a risk factor for parkinsonism. Neurology 73, 1208–1214.

Palikaras K, Tavner-Marakis N (2012) Mitophagy in neurodegeneration and aging. Front. Genet. 3, 297.
Parkinson’s disease as a result of aging, M. Rodriguez et al. 307

Riederer P, Wuketch S (1976) Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis. J. Neurol. Neurosurg. Psychiatry 39, 277–301.
Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdum MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515–520.
Robinson DS, Sourkes TL, Nies A, Harris LS, Spector S, Bartlett DL, Kaye IS (1977) Monoamine metabolism in human brain. Arch. Gen. Psychiatry 34, 89–92.
Rodriguez M, Castro R (1991) Apomorphine lowers dopamine synthesis for up to 48 h: implications for drug sensitization. Neuropsychopharmacology 2, 365–368.
Rodriguez Diaz M, Abdala P, Barroso-Chinea P, Obeso J, Gonzalez-Hernandez T (2001) Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson’s disease. Behav. Brain Res. 122, 79–92.
Rodriguez M, Gonzalez-Hernandez T (1999) Electrophysiological and morphological evidence for a GABAergic nigrostratal pathway. J. Neurosci. 19, 4682–4694.
Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T (2001) Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson’s disease. Exp. Neurol. 169, 163–181.
Rodriguez M, Sabate M, Rodriguez-Sabate C, Morales I (2012) The role of non-synaptic extracellular glutamate. Brain Res. Bull. 93, 17–26.
Rodriguez Navarro JA, Casarejos MJ, Menendez J, Solano RM, Rodol J, Gomez A, Yevenes JG, Mena MA (2007) Mortality, oxidative stress and tau accumulation during ageing in parkin null mice. J. Neurochem. 103, 98–114.
Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int. Rev. Neurol. 82, 235–246.
Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (2007) Mitochondrial microheteromelasy and a theory of aging and age-related disease. Rejuvenat. Res. 8, 172–198.
Rofonov MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta Neuropathol. 119, 7–35.
Sahol RS, Brunk UT (1992) Mitochondrial production of pro-oxidants and cellular senescence. Mutat. Res. 275, 295–304.
Sahol RS, Orr WC (2012) The redox stress hypothesis of aging. Free Radic. Biol. Med. 52, 539–555.
Sahol RS, Weindruch R (1996) Oxidative stress, caloric restriction, and aging. Science 273, 59–63.
Song YJ, Halliday GM, Holton JL, Lashley T, O’Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz T (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 68, 1073–1083.
Sossi V, de La Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, Stossel AJ, Ruth TI (2002) Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18F-fluorodopa data. J. Cereb. Blood Flow Metab. 22, 232–239.
Srivastava S, Haigis MC (2011) Role of sirtuins and calorie restriction in neuroprotection: implications in Alzheimer’s and Parkinson’s diseases. Curr. Pharm. Des. 17, 3418–3433.
Stark AK, Pakkenberg B (2004) Histological changes of the dopaminergic nigrostratal system in aging. Cell Tissue Res. 318, 81–92.
Stefanis L, Larsen KE, Rideout HI, Sulzer D, Greene LA (2001) Expression of AS3T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9495–9560.
Sterky FH, Lee S, Wibom R, Olson L, Larsson NG (2011) Impaired mitochondrial transport and Parkin-independent degeneration of respiratory chain-deficient dopamine neurons in vivo. Proc. Natl Acad. Sci. USA 108, 12937–12942.
Streit WJ (2002) Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 40, 133–139.
Streit WJ, Graeber MB, Kreutzberg GW (1989) Expression of the antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp. Neurol. 105, 115–126.
Streit WJ, Miller KR, Lopes KO, Njie E (2008) Microglial degeneration in the aging brain—bad news for neurons? Front. Biosci. 13, 3423–3438.
Subramaniam SR, Cheesefield MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog. Neurobiol. 106–107, 17–32.
Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T, Tateno Y (1991) Age-related changes in locus ceruleus on neuromelanin magnetic resonance imaging at 3 Tesla. Magn. Reson. Med. Sci. 10, 198–203.
Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP, Bennett JP Jr, Davis RE, Parker WD Jr (1996) Origin and functional consequences of the complex I defect in Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 19–28.
Sohal RS, Brunk UT (1992) Mitochondrial production of pro-oxidants and cellular senescence. Mutat. Res. 275, 295–304.
Sohal RS, Orr WC (2012) The redox stress hypothesis of aging. Free Radic. Biol. Med. 52, 539–555.
Sohal RS, Weindruch R (1996) Oxidative stress, caloric restriction, and aging. Science 273, 59–63.
Song YJ, Halliday GM, Holton JL, Lashley T, O’Sullivan SS, McCann H, Lees AJ, Ozawa T, Williams DR, Lockhart PJ, Revesz T (2009) Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. 68, 1073–1083.
Sossi V, de La Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, Stossel AJ, Ruth TI (2002) Increase in dopamine turnover occurs early in Parkinson’s disease: evidence from a new modeling approach to PET 18F-fluorodopa data. J. Cereb. Blood Flow Metab. 22, 232–239.

© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Valente EM, Abdou-Sleiman PM, Caputo V, Muijt MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gils WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004a) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.

Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, Romito L, Albanese A, Dallapiccola B, Bentivoglio AR (2004b) PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56, 336–341.

Van Humbeeck C, Cornelissen T, Hofkens H, Mandemakers W, Gevaert K, De Strooper B, Vandenberghhe W (2011) Parkin interacts with Ambra1 to induce mitophagy. J. Neurosci. 31, 10249–10261.

Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB (2005) Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 64, 728–730.

Venkatapesha C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Biochem. J. 445, 543–554.

Wang Y, Chan GL, Holden JE, Dobko T, Salvi S, Cortelli P, Gils WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004a) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158–1160.

Wang Y, Chan GL, Holden JE, Dobko T, Salvi S, Cortelli P, Gils WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004a) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160.

Wang Y, Chan GL, Holden JE, Dobko T, Salvi S, Cortelli P, Gils WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW (2004a) Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160.

Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ (2009) Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48, 2045–2052.

Weisskopf MG, Knekt P, O’Reilly EJ, Lytinen J, Reunanen A, Laden F, Altschul L, Ascherio A (2010) Persistent organochlorine pesticides in serum and risk of Parkinson disease. Neurology 74, 1055–1061.

Werner CJ, Heym-van Hausssen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci. 6, 8.

Wilson PD, Franks LM (1975) The effect of age on mitochondrial ultrastructure. Gerontologia 21, 81–94.

Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. Epidemiol. 26(Suppl 1), S1–S58.

Wong E, Cuervo AM (2010) Autophagy gone awry in neurodegenerative diseases. Nat. Neurosci. 13, 805–811.

Wood Kaczmar A, Gandhi S, Yao Z, Abramov AY, Miljan E, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SJ, Wood NW (2008) PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 3, e2455.

Yang ML, Hasadiri L, Woods WS, George JM (2010) Dynamic transport and localization of alpha-synuclein in primary hippocampal neurons. Mol. Neurodegener. 5, 9.

Yen WL, Klionsky DJ (2008) How to live long and prosper: autophagy, senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am. J. Physiol. Endocrinol. Metab. 299, E110–E116.

Zweig RM, Jankel WR, Hedreen JC, Mayhew R, Price DL (1989) The pedunculo-pontine nucleus in Parkinson’s disease. Ann. Neurol. 26, 41–46.

© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.